Minoxidil

TAIPEI, March 26, 2025 /PRNewswire/ -- AnHorn Medicines, a pioneering AI-driven new drug discovery company, is pleased to announce that, AH-001, a first-in-class protein degrader for androgenetic alopecia (AGA), has officially entered Phase I clinical trial in the United States. The first subject was dosed this week, marking a major milestone in the development of this innovative therapy. Continue Reading AnHorn Medicines AH-001 represents a groundbreaking advancement in AGA treatment with its novel mechanism of action as a selective protein degrader. Unlike traditional treatments that focus on inhibiting specific enzymes or stimulating hair follicles, AH-001 precisely targets and eliminates key proteins linked to hair loss. This innovative approach has the potential to offer a more effective and long-lasting solution for millions of individuals suffering from AGA worldwide. The global market for AGA treatments is projected to exceed $10 billion by 2030, driven by the growing demand for more effective and sustainable therapies. Current treatments, such as finasteride and minoxidil, have limitations in efficacy and potential side effects, leaving a significant unmet medical need. AH-001's innovative mechanism has the potential to be a game-changer, offering a new level of therapeutic benefit for AGA patients. AnHorn's success in developing AH-001 is driven by its proprietary AI-powered drug discovery platform. By leveraging artificial intelligence, AnHorn has impressively accelerated the identification of promising protein degraders, streamlining the early-stage drug development process. This AI-powered approach has not only improved the efficiency of drug discovery but has also provided valuable insights into targeting complex biological pathways, reinforcing AnHorn's leadership in next-generation therapeutic innovation. With the launch of the Phase I study, AnHorn remains committed to advancing AH-001 through clinical development, aiming to deliver a transformative solution to the market. The company will continue to provide updates as the trial progresses. About AnHorn Medicines AnHorn is a clinical-stage biotechnology company dedicated to revolutionizing drug discovery through AI-powered innovation. By integrating artificial intelligence with cutting-edge molecular research, AnHorn is pioneering new treatments for conditions with high unmet medical needs. AH-001 is the company's first leading program through its AI-driven platform, exemplifying its mission to create breakthrough therapies that improve patient outcomes. SOURCE AnHorn Medicines WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

NEW YORK, March 18, 2025 /PRNewswire/ -- Small amounts of a common antibiotic and anti-inflammatory drug can curb symptoms where a misplaced immune reaction (e.g., autoimmunity) can cause permanent hair loss, a new study shows. This regimen may also come with fewer side effects than higher doses of the medication. Continue Reading Led by researchers at NYU Langone Health, the study explored lymphocytic scarring alopecia, a rare skin condition in which the body's immune cells damage hair follicles, leading to hair loss and scarring. Physicians typically treat this chronic disorder with relatively high doses of the antibiotic doxycycline, often for prolonged periods of time. However, the drug can trigger nausea, vomiting, and rashes and may discourage patients from continuing to take it, the study authors say. As a result, the team set out to determine whether lower doses could work instead. Besides warding off unpleasant side effects, lower doses of the drug may also safeguard gut health. Post this The findings in 241 men and women treated for several forms of lymphocytic scarring alopecia revealed that lower doses (usually 20 milligrams taken twice daily) and higher doses (as much as 100 milligrams taken twice daily) of doxycycline were equally effective. Specifically, the researchers found no significant difference between the two groups on evaluations of scalp inflammation, patients' perception of the severity of their hair loss, and clinical measurements of hair density, hair-shaft diameter, and hairline recession. In addition, while 23% of those on the high-dose regimen experienced common negative side effects of doxycycline, only 12% of those taking smaller doses of the drug did so. Another key finding was that while 25% of the high-dose group stopped taking doxycycline altogether due to gastrointestinal issues, only 16% of the low-dose group stopped treatment due to this side effect. "Our findings suggest that physicians can prescribe lower doses of doxycycline to patients struggling with lymphocytic scarring alopecia without compromising the efficacy and anti-inflammatory benefit of the therapy," said study co-lead author Carli Needle, BA. Needle, a medical student at NYU Grossman School of Medicine, adds that besides warding off unpleasant side effects, lower doses of the drug may also safeguard gut health. Doxycycline, she notes, is known to harm the helpful bacteria that live in the digestive tract and bolster the body's defenses against disease-causing microbes. However, past studies have shown that drug doses below 40 milligrams are less risky for beneficial microbes. The new study is the first to directly compare the efficacy of different-size doses of doxycycline to treat lymphocytic scarring alopecia, says Needle. A report on the findings is publishing March 18 in the Journal of the American Academy of Dermatology. For the study, the research team collected data from electronic medical records of patients with scarring alopecia treated at NYU Langone Health between 2009 and 2023. Of these, about 27% had been prescribed low doses of doxycycline and nearly 73% were on traditional high-dose regimens. Next, the team ran a statistical analysis to compare the two groups. The researchers discounted from their analysis any effects of other medications that commonly accompany this treatment, such as the hair-growth drug minoxidil. According to the authors, a further advantage of reducing doxycycline doses is that experts have linked the drug to the rise of dangerous bacterial populations that can survive antibiotic treatments. Clinicians worldwide are now seeking to combat such antibiotic resistance by limiting how often and in what quantities they prescribe these drugs, a practice called antibiotic stewardship. "Our results offer another avenue for healthcare providers to protect patients from harm caused by unnecessary antibiotic use and address the rise of drug-resistant strains of microbes," said study co-lead author Anna Brinks, BA, a medical student at NYU Grossman School of Medicine. "Alopecia can have a devastating effect on self-image and can lead to social judgment, depression, and anxiety," added study co-senior author Kristen Lo Sicco, MD. "Studies that advance the management of these conditions are critical to addressing not only hair loss itself, but also the psychological and social consequences that accompany it." Lo Sicco, an associate professor in the Ronald O. Perelman Department of Dermatology at NYU Grossman School of Medicine, says that the researchers next plan to repeat their work in a larger and more diverse group, as the study patients were mostly White. In addition, she says the team intends to explore the triggers that cause lymphocytic scarring alopecia, which remain poorly understood. Study funding was provided by NYU Langone Health. In addition to Needle, Brinks, and Lo Sicco, other NYU Langone researchers involved in the study are Akshay Pulavarty, MD, MPH; Caitlin Kearney, BS; Ambika Nohria, BA; Deesha Desai, BS; and Jerry Shapiro, MD. About NYU Langone Health NYU Langone Health is a fully integrated health system that consistently achieves the best patient outcomes through a rigorous focus on quality that has resulted in some of the lowest mortality rates in the nation. Vizient, Inc., has ranked NYU Langone the No. 1 comprehensive academic medical center in the country for three years in a row, and U.S. News & World Report recently placed nine of its clinical specialties among the top five in the nation. NYU Langone offers a comprehensive range of medical services with one high standard of care across seven inpatient locations, its Perlmutter Cancer Center, and more than 300 outpatient locations in the New York area and Florida. With $14.2 billion in revenue this year, the system also includes two tuition-free medical schools, in Manhattan and on Long Island, and a vast research enterprise with over $1 billion in active awards from the National Institutes of Health. Media Inquiries: Shira Polan Phone: 212-404-4279 [email protected] SOURCE NYU Grossman School of Medicine and NYU Langone Health WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED